Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10249193 | 0.96 | DOT1L (0.36) | DOT1LPRMT5WDR77 | |
| SCHEMBL9104911 | 0.95 | DOT1L (0.40) | DOT1LPRMT5WDR77 | |
| SCHEMBL9104905 | 0.95 | DOT1L (0.40) | DOT1LPRMT5WDR77 | |
| SCHEMBL10249266 | 0.94 | DOT1L (0.35) | DOT1L | |
| SCHEMBL10252657 | 0.94 | DOT1L (0.34) | DOT1LPRMT5WDR77 | |
| SCHEMBL10252650 | 0.94 | DOT1L (0.34) | DOT1LPRMT5WDR77 | |
| SCHEMBL10249093 | 0.93 | DOT1L (0.34) | DOT1L | |
| SCHEMBL10249274 | 0.93 | DOT1L (0.33) | DOT1LPRMT5WDR77 | |
| SCHEMBL10249262 | 0.92 | DOT1L (0.33) | DOT1LPRMT5WDR77 | |
| SCHEMBL9109166 | 0.91 | CCRL2 (0.37) | DOT1LPRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-9096634-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2014-02-20 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885WDR77 32/4885 |
| US-20140051654-A1 | Substituted Purine and 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885WDR77 32/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | DOT1L 6/4885PRMT5 37/4885WDR77 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.